MDXH MDXH
Company Profile ↓Company Overview
MDXH (MDXH) is a publicly traded company listed on with a market capitalization of $22.09M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 42.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $107.88M (+19.8% YoY); net profit $-33.52M.
- Trailing 12 Months Year-on-year growth — revenue +19.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 42.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 42.79% |
| 1 Year: | 19.80% |
Stock Price Performance
| 1 Year: | -82.45% |
| 6 Months: | -87.96% |
| 3 Months: | -78.32% |
| 1 Month: | -7.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.59 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 42.8% over 5 years.
CONS
- Trading 91.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 24.29M | 26.61M | 27.43M | 29.55M | 27.39M |
| Cost of Revenue | - | 8.79M | 9.04M | 9.56M | 10.86M | 10.77M |
| Gross Profit | - | 15.50M | 17.57M | 17.88M | 18.69M | 16.61M |
| Operating Expenses | - | 20.09M | 19.48M | 20.52M | 24.91M | 23.92M |
| Operating Income | - | -4.59M | -1.92M | -2.64M | -6.22M | -7.30M |
| EBITDA | - | -1.65M | 770.00K | 114.00K | -11.99M | 2.47M |
| Interest Expense | - | 5.18M | 6.29M | 5.88M | -5.49M | 8.95M |
| Pretax Income | - | -9.07M | -7.79M | -8.02M | -10.50M | -8.87M |
| Tax Provision | - | 137.00K | -416.00K | -6.00K | -1.57M | 0 |
| Net Income | - | -9.21M | -7.37M | -8.01M | -8.93M | -8.87M |
| Diluted EPS | -0.14 | -0.19 | - | -0.16 | -0.17 | -0.17 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 37.05M | 70.19M | 90.05M | 107.88M |
| Cost of Revenue | - | 17.84M | 26.26M | 34.91M | 38.24M |
| Gross Profit | - | 19.22M | 43.93M | 55.14M | 69.63M |
| Operating Expenses | - | 57.63M | 70.67M | 79.17M | 85.00M |
| Operating Income | - | -38.41M | -26.74M | -24.03M | -15.37M |
| EBITDA | - | -36.50M | -30.66M | -22.02M | -14.55M |
| Interest Expense | - | 2.64M | 5.58M | 7.63M | 11.62M |
| Pretax Income | - | -44.04M | -43.10M | -37.69M | -35.38M |
| Tax Provision | - | 0 | 1.00K | 382.00K | -1.86M |
| Net Income | - | -44.04M | -43.10M | -38.07M | -33.52M |
| Diluted EPS | - | -2.80 | -1.66 | -1.16 | -0.67 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 119.14M | 129.13M | 157.33M | 147.95M |
| Current Assets | - | 29.15M | 38.16M | 66.89M | 53.41M |
| Cash & Equivalents | - | 15.50M | 22.38M | 46.80M | 29.03M |
| Inventory | - | 2.33M | 2.78M | 3.87M | 6.74M |
| Receivables | - | 9.36M | 11.09M | 14.44M | 14.68M |
| Total Liabilities | - | 109.82M | 121.92M | 142.49M | 160.05M |
| Current Liabilities | - | 18.28M | 19.52M | 42.66M | 49.53M |
| Long Term Debt | - | 34.91M | 35.56M | 50.97M | 76.20M |
| Total Debt | - | 39.79M | 41.27M | 60.06M | 86.60M |
| Total Equity | - | 9.31M | 7.21M | 14.84M | -12.09M |
| Shares Outstanding | - | 16.29M | 27.29M | 49.50M | 51.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -34.12M | -21.50M | -18.53M | -2.19M |
| Investing Cash Flow | - | -29.04M | -3.93M | -1.64M | -18.56M |
| Financing Cash Flow | - | 20.72M | 32.28M | 44.60M | 2.96M |
| Capital Expenditure | - | -4.16M | -5.02M | -2.16M | -1.16M |
| Free Cash Flow | - | -38.28M | -26.52M | -20.69M | -3.35M |
| Net Change in Cash | - | -42.44M | 6.85M | 24.43M | -17.78M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 51.9% | 62.6% | 61.2% | 64.5% |
| Operating Margin % | - | -103.7% | -38.1% | -26.7% | -14.2% |
| Net Margin % | - | -118.9% | -61.4% | -42.3% | -31.1% |
| ROE % | - | -472.8% | -597.9% | -256.5% | 277.2% |
| ROCE % | - | -38.1% | -24.4% | -21.0% | -15.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDXH
Mdxhealth schedules live Q&A on second-quarter results Aug. 13 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNd2JWV3RQOXlFSFpyb2s2Y1JhR29ER00yTVFKTG1vQmZrdHg4TUxVMmhvNzhkUHVrOHctaW5ScVdieWgzREZySTNLSHFMdDFZem1xSHJwc2Q3alY3MTVOd2tRN0FNcDhpaUhzREFnUGtFQW5TRGswUEEzdUN1YnNDVU9pTlBlYktSYUlmVG…
MDXH Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFA5LU5YWjZtWFJIM0xjZDJ0YnpVYU5neFVIeHlURDdYcnhuT25idktkNFBYVGRzYVlvdWNsTGViN0dYNk9JeUxVV1VnVC1kRWJacGVxS21ydWZQb2UyN1RjZWdqcTI3U3Fna1BEcDJYVnZVd3JoS0lpX0VB?oc=5" target="_blank">MDX…
mdxhealth Receives Nasdaq Notice of Minimum Market Value Deficiency - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPQ3hkYTZIRXEydlF0R1ZLQ3N0am1MQVlVVE5aWXhvNG05YmdZajRuRDRDYkE4NnpKMTJ2VjFPOGwtUEtlNjJHYzAtYUgwWVlmaGZqS3ZUNlpYQzJ3RGhodUM0bzRSZlRCbDhDNWQ1N18yemJEaW9vSlpiaURFbU9oMEtkQTJQdjlkVk5nTX…
Loss-Making MDxHealth SA (NASDAQ:MDXH) Expected To Breakeven In The Medium-Term - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQNVV0RDZJNFVScWJKTUxSSmQ2MnBleFhZSHptRDdIdnZhcG92Q3FJMHFhNXI0dE1iZk5teThKdlRwck1nU3dqUkp2VnpfWVUtNTVXcFBmOGpabmxpR21JYUdSVXcxeDZmNm03TEVZcHpWTVo4ZWJBcFJJaVRaeXE3d29iUQ?oc=5" targe…
MDXH Faces Challenges Amid Strategic Revisions and Medicare Disp - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiqgJBVV95cUxNRXJTdk56N0JXMTdZeFQwU1JBRFptZnB1bzhhM2F2SU1tVGR3Snp3OHYwY0N6dzAxQU5tVlAtM29TMWVyVFJvNHVFb2NPbkRfUm44TU0zcmF0b0tkZEdxMklLSWJPdEtjWlZPYmNNcWl4Uk52Y1hHZU0wWWZTZG5lV1pNN01LXzlhYVhhTk…
TD Cowen cuts MDxHealth stock price target on Medicare dispute - Investing.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOZWxibm5keFVKNVYwa1psbDA3NW55ZVYyRFl5aG5QdnBJZ2Y1Vk00elNPMUpNRThlSzczTTl2eGF2dFQ1QVY2MkdfZ19BZGVRNl9mUE5YNkVraGtMSS0ySHA4cDE2enlXeVZCbFZzdjJBTTdOZTJIVnpDcHgwYUVlQ3hGY0lkY1FZRXFIQl…
MDXH — Frequently Asked Questions
What is the current share price of MDXH?
As of 2026-08-05 17:25 PDT, MDXH trades at $0.43 on NASDAQ/NYSE. Its 52-week range is $0.40 to $5.00.
What is the market capitalisation of MDXH?
MDXH has a market capitalisation of $22.09M on NASDAQ/NYSE.
What is the P/E ratio of MDXH?
MDXH trades at a trailing price-to-earnings (P/E) ratio of -0.64. Its price-to-book (P/B) ratio is -1.83.
Is MDXH a good stock to buy?
This page provides a data-driven analysis of MDXH, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.